Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Ype de Jong studied medicine at the University of Amsterdam Medical School. After completing his master's in Amsterdam he conducted research into the immunopathogenesis of Crohn’s disease at the Beth Israel Deaconess Medical Center in Boston, with which he obtained his PhD. He subsequently completed his Internal Medicine internship and residency at the Mount Sinai Hospital in New York, followed by a fellowhip in Gastroenterology at the same institution. He currently is an Assistant Professor of Medicine at Weill Cornell and Guest Investigator in the Laboratory of Virology and Infectious Disease at Rockefeller University. His laboratory research focuses on human hepatocyte biology in liver diseases and gene therapy. 

Highlights

  1. 1
    Proceedings of the National Academy of Sciences of the United States of America · 2020
    CMCharles M. RiceYPYpe P. de Jong
    PMID: 31915293PMCID: PMC6983380DOISenior author59 citations
  2. 2
    Nature biotechnology · 2025
    YPYpe P. de Jong
    PMID: 39881028DOISenior author1 citations
  3. 3
    Cell reports · 2022
    DCDavid CohenBEBaran ErsoyCMCharles M. RiceYPYpe P. de Jong
    PMID: 36103835PMCID: PMC11587767DOISenior author29 citations

Publications

89 publications

Funding

12 grantsView NIH portfolio on RePORTER ↗

Active

7 grants
  • MPI
    Elucidating the host and viral determinants of treatment response in chronic hepatitis B
    National Institute of Allergy and Infectious Diseases · 2026–2031 · via Rockefeller University
    R01AI190067-01A1
  • MPI
    Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology
    National Institute of Allergy and Infectious Diseases · 2022–2030 · via The Rockefeller University· 2 renewals
    R01AI150275-07
  • Sub-PI
    Enhancing Immune Regulation In Gene Therapy For Hemophilia
    National Heart, Lung, and Blood Institute · 2016–2029 · via Indiana University· 4 renewals
    R01HL131093-10
  • Sub-PI
    A proteomics atlas of HIV/HBV co-infections for curing HBV
    National Institute of Allergy and Infectious Diseases · 2024–2029 · via Emory University
    No publications yet
    R01Al181682-03
  • Sub-PI
    Impact of HIV/HBV co-infections on circadian rhythm
    National Institute of Diabetes and Digestive and Kidney Diseases · 2024–2029 · via Emory University
    DP1DK139804-03
  • MPI
    Breaching the species barrier: Towards an immunocompetent HBV-susceptible mouse model
    National Institute of Allergy and Infectious Diseases · 2024–2029 · via Rockefeller University
    R01AI183884-03
  • Sub-PI
    Core B: Human Hepatocyte and Discovery
    National Heart, Lung, and Blood Institute · 2022–2027 · via Indiana University· 2 renewals
    P01HL160472-05
Completed grants (5)
  • Sub-PI
    Virus-host interactions for a cure against HBV
    National Institute of Allergy and Infectious Diseases · 2024–2025 · via Emory University
    R56AI182395-01
  • PI
    Modeling alcohol toxicity in human hepatocytes
    National Institute on Alcohol Abuse and Alcoholism · 2019–2025
    R01AA027327-05
  • MPI
    In search of an HBV cure: novel model systems and targets
    National Institute of Allergy and Infectious Diseases · 2019–2024 · via Rockefeller University
    R01AI143295-05
  • PI
    The role of innate immune evasion in hepatitis C virus infection
    NIDDK · 2011–2016 · via NIH RePORTER
    K08DK090576-05
  • KP
    Integrated vs. Separate Care for Hepatitis C, Substance Abuse, and HIV Prevention
    National Institute on Drug Abuse · 2010–2015 · via State University of New York Downstate Medical Center
    R01DA029512-04

Mentoring

6 menteesAll publications with mentees →

External relationships

Advisory/Scientific Board Member

Kriya Therapeutics